# A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.

> **NCT00425282** · PHASE3 · COMPLETED · sponsor: **SK Life Science, Inc.** · enrollment: 566 (actual)

## Conditions studied

- Epilepsy
- Epilepsy, Focal
- Seizure Disorder
- Complex Partial Seizures
- Epilepsy, Complex Partial

## Interventions

- **DRUG:** RWJ-333369

## Key facts

- **NCT ID:** NCT00425282
- **Lead sponsor:** SK Life Science, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 566 (ACTUAL)
- **Last updated:** 2012-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00425282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00425282, "A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00425282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*